Clinical trials in Madrid – page 142

3 330 clinical trials in Madrid, Spain across 24 research sites. Every trial is listed in the EU Clinical Trials Register and updated daily.

Our site in SpainEnsayosClinicos.es

Madrid at a glance

3 330

clinical trials

Research sites24

Quick filters

3 330 trials in Madrid

Open in trial search

Chronic lymphocytic leukaemia+3

Not recruiting

Evaluation of Safety and Efficacy of Zilovertamab Vedotin and Nemtabrutinib in Aggressive and Indolent B-cell Malignancies

InvestigationalNo placebo

Evaluation of Safety and Efficacy of Zilovertamab Vedotin and Nemtabrutinib in Aggressive and Indolent B-cell Malignancies

InvestigationalNo placebo

Spain

Participants:18–64 years · 65+ years
Substances:Nemtabrutinib
Sponsor:Merck Sharp & Dohme LLC

Contact Research Centre

Neoplasm

Not recruiting

A study to evaluate the safety and effectiveness of KD033 in patients with advanced or metastatic solid tumors

InvestigationalNo placebo

A study to evaluate the safety and effectiveness of KD033 in patients with advanced or metastatic solid tumors

InvestigationalNo placebo

Spain

Participants:18–64 years · 65+ years
Sponsor:Kadmon Corporation LLC

Contact Research Centre

Neoplasm malignant

Not recruiting

Effect of Food on Absorption of 2-(3-(3,5-dimethyltriazol-4-yl)-5-((s)-oxan-4-yl(phenyl)methyl)pyrido(3,2-b)indol-7-yl)propan-2-ol in Advanced Solid Tumors Participants

InvestigationalNo placebo

Effect of Food on Absorption of 2-(3-(3,5-dimethyltriazol-4-yl)-5-((s)-oxan-4-yl(phenyl)methyl)pyrido(3,2-b)indol-7-yl)propan-2-ol in Advanced Solid Tumors Participants

InvestigationalNo placebo

Spain

Participants:18–64 years · 65+ years
Substances:2-(3-(3,5-Dimethyltriazol-4-Yl)-5-((S)-Oxan-4-Yl(Phenyl)Methyl)Pyrido(3,2-B)Indol-7-Yl)Propan-2-Ol
Sponsor:Bristol-Myers Squibb Services Unlimited Company

Contact Research Centre

Osteosarcoma

Not recruiting

Efficacy and Safety of Maintenance Cabozantinib Plus Best Supportive Care in Pediatric and AYA Patients with Unresectable Residual Osteosarcoma

Registered drugNo placebo

Efficacy and Safety of Maintenance Cabozantinib Plus Best Supportive Care in Pediatric and AYA Patients with Unresectable Residual Osteosarcoma

Registered drugNo placebo

Spain

Participants:0–17 years · 18–64 years
Substances:Cabozantinib
Sponsor:Ipsen Innovation

Contact Research Centre

Metastatic neoplasm

Not recruiting

Phase 1 Study of NG-641 with Nivolumab and Pembrolizumab in Patients with Metastatic or Advanced Epithelial Tumors

Registered drugNo placebo

Phase 1 Study of NG-641 with Nivolumab and Pembrolizumab in Patients with Metastatic or Advanced Epithelial Tumors

Registered drugNo placebo

Spain

Participants:18–64 years · 65+ years
Substances:Nivolumab
Sponsor:Akamis Bio Limited

Contact Research Centre

Nicotine dependence

Not recruiting

A study to evaluate how cytisinicline works in patients with nicotine addiction and kidney problems or those undergoing dialysis

InvestigationalNo placebo

A study to evaluate how cytisinicline works in patients with nicotine addiction and kidney problems or those undergoing dialysis

InvestigationalNo placebo

Spain

Participants:18–64 years · 65+ years · Healthy volunteers
Substances:Cytisinicline
Sponsor:Achieve Life Sciences Inc.

Contact Research Centre

Conjunctivitis allergic

Not recruiting

Study of bilastine for effectiveness, safety and quality of life in children aged 6 to 12 years with allergic rhinoconjunctivitis

Registered drugNo placebo

Study of bilastine for effectiveness, safety and quality of life in children aged 6 to 12 years with allergic rhinoconjunctivitis

Registered drugNo placebo

Spain

Participants:0–17 years
Substances:Bilastine
Sponsor:A. Menarini Industrie Farmaceutiche Riunite S.r.l.

Contact Research Centre

Hormone-dependent prostate cancer+1

Not recruiting

A Study of Mevrometostat and Enzalutamide for Men with Metastatic Castration-Sensitive Prostate Cancer Who Have Not Received Hormonal Therapy or Chemotherapy

Registered drug

A Study of Mevrometostat and Enzalutamide for Men with Metastatic Castration-Sensitive Prostate Cancer Who Have Not Received Hormonal Therapy or Chemotherapy

Registered drug

Spain

Participants:18–64 years · 65+ years
Substances:Enzalutamide
Sponsor:Pfizer Inc.

Contact Research Centre

Warm autoimmune haemolytic anaemia+1

Not recruiting

Study of ianalumab for adults with primary immune thrombocytopenia or warm-antibody autoimmune hemolytic anemia who previously responded to ianalumab

Registered drugNo placebo

Study of ianalumab for adults with primary immune thrombocytopenia or warm-antibody autoimmune hemolytic anemia who previously responded to ianalumab

Registered drugNo placebo

Spain

Participants:18–64 years · 65+ years
Substances:Danazol
Sponsor:Novartis Pharma AG

Contact Research Centre

Dementia Alzheimer's type

Not recruiting

Study of Trontinemab Compared to Placebo for Patients with Early Symptomatic Alzheimer's Disease

Registered drug

Study of Trontinemab Compared to Placebo for Patients with Early Symptomatic Alzheimer's Disease

Registered drug

Spain

Participants:18–64 years · 65+ years
Substances:Florbetaben (18F)
Sponsor:F. Hoffmann-La Roche AG

Contact Research Centre

Dementia Alzheimer's type

Not recruiting

A study testing trontinemab compared to placebo in patients with early Alzheimer's disease including mild cognitive impairment and mild dementia

Registered drug

A study testing trontinemab compared to placebo in patients with early Alzheimer's disease including mild cognitive impairment and mild dementia

Registered drug

Spain

Participants:18–64 years · 65+ years
Substances:Florbetaben (18F)
Sponsor:F. Hoffmann-La Roche AG

Contact Research Centre

Multiple sclerosis

Not recruiting

A Study Comparing Two Forms of Ocrelizumab Given Under the Skin in Patients with Multiple Sclerosis

Registered drugNo placebo

A Study Comparing Two Forms of Ocrelizumab Given Under the Skin in Patients with Multiple Sclerosis

Registered drugNo placebo

Spain

Participants:18–64 years
Substances:Ocrelizumab
Sponsor:F. Hoffmann-La Roche AG

Contact Research Centre

Other cities in Spain

The busiest research cities in the country

All 218 cities in Spain

Clinical research in Madrid

What the registry says about research in the country

01 Autoimmune and Inflammatory Conditions

Investigating novel treatments for cutaneous lupus erythematosus and immune thrombocytopenia, with studies evaluating new therapeutic approaches to manage these challenging conditions.

Lupus skin manifestations
Platelet disorders
Immune system regulation

Research focuses on improving treatment outcomes and quality of life for patients with autoimmune disorders.

02 Metabolic and Endocrine Disorders

Clinical trials examining innovative therapies for Type 1 Diabetes in combination with weight management, targeting both glycemic control and obesity-related complications.

Diabetes management
Weight control
Metabolic health

Studies aim to develop comprehensive treatment approaches for complex metabolic conditions.

03 Neurological Conditions

Breakthrough research in multiple sclerosis and acute ischemic stroke, exploring new therapeutic options for both pediatric and adult populations.

MS treatment in young patients
Stroke intervention
Neurological recovery

Focus on developing targeted treatments to improve neurological outcomes and patient care.

04 Infectious Disease Prevention

Comprehensive vaccine studies targeting respiratory syncytial virus, influenza, and herpes zoster, with particular attention to vulnerable populations.

Vaccine development
Immune response
Prevention strategies

Research aims to enhance protection against common and serious infectious diseases.

05 Oncology Research

Innovative studies in mantle cell lymphoma and bladder cancer, exploring combination therapies and targeted treatments to improve patient outcomes.

Lymphoma treatment
Bladder cancer therapy
Immunotherapy approaches

Focus on developing more effective and personalized cancer treatments.

Back to Spain All countries